A changing treatment landscape for multiple sclerosis: challenges and opportunities

被引：47

作者：

Piehl, F. ^{[1
]}

机构：

[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden

来源：

JOURNAL OF INTERNAL MEDICINE | 2014年 / 275卷 / 04期

关键词：

multiple sclerosis; immunomodulatory therapy; biological therapies; randomized controlled trial; PLACEBO-CONTROLLED TRIAL; FUMARIC-ACID ESTERS; MEMORY T-CELLS; DOUBLE-BLIND; NATALIZUMAB TREATMENT; CONTROLLED PHASE-3; INTERFERON-BETA; DISEASE-ACTIVITY; BREAKTHROUGH DISEASE; GLATIRAMER ACETATE;

D O I：

10.1111/joim.12204

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.

引用

页码：364 / 381

页数：18

共 89 条

[1] Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis [J].

Axelsson, Markus ;

Malmestrom, Clas ;

Gunnarsson, Martin ;

Zetterberg, Henrik ;

Sundstrom, Peter ;

Lycke, Jan ;

Svenningsson, Anders .

MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (01) :43-50

[2] Interferon-β treatment for multiple sclerosis [J].

Bermel, Robert A. ;

Rudick, Richard A. .

NEUROTHERAPEUTICS, 2007, 4 (04) :633-646

[3] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[4] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[5] Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis [J].

Bornsen, Lars ;

Christensen, Jeppe Romme ;

Ratzer, Rikke ;

Oturai, Annette Bang ;

Sorensen, Per Soelberg ;

Sondergaard, Helle Bach ;

Sellebjerg, Finn .

PLOS ONE, 2012, 7 (11)

[6] Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination [J].

Brueck, Wolfgang ;

Pfoertner, Ramona ;

Trinh Pham ;

Zhang, Jingya ;

Hayardeny, Liat ;

Piryatinsky, Victor ;

Hanisch, Uwe-Karsten ;

Regen, Tommy ;

van Rossum, Denise ;

Brakelmann, Lars ;

Hagemeier, Karin ;

Kuhlmann, Tanja ;

Stadelmann, Christine ;

John, Gareth R. ;

Kramann, Nadine ;

Wegner, Christiane .

ACTA NEUROPATHOLOGICA, 2012, 124 (03) :411-424

[7]

Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1

[8] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[9] Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects [J].

Cohen, Jeffrey A. ;

Reingold, Stephen C. ;

Polman, Chris H. ;

Wolinsky, Jerry S. .

LANCET NEUROLOGY, 2012, 11 (05) :467-476

[10] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis [J].

Cohen, Jeffrey A. ;

Barkhof, Frederik ;

Comi, Giancarlo ;

Hartung, Hans-Peter ;

Khatri, Bhupendra O. ;

Montalban, Xavier ;

Pelletier, Jean ;

Capra, Ruggero ;

Gallo, Paolo ;

Izquierdo, Guillermo ;

Tiel-Wilck, Klaus ;

de Vera, Ana ;

Jin, James ;

Stites, Tracy ;

Wu, Stacy ;

Aradhye, Shreeram ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :402-415

← 1 2 3 4 5 6 7 8 9 →